CorMedix (CRMD) Non-Current Assets (2010 - 2026)
CorMedix (CRMD) posted Non-Current Assets of $459.1 million for Q4 2025, down 6.56% sequentially from $491.3 million in Q3 2025, and up 10649.03% YoY from N/an in Q4 2024.
CorMedix (CRMD) Non-Current Assets (2010 - 2026) Analysis & Trends
CorMedix has reported Non-Current Assets for 15 years, with the latest figure at $459.1 million in Q4 2025.
- Quarterly Non-Current Assets rose 10649.03% year-over-year to $459.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $959.7 million (up 5275.36% YoY) and the FY2025 annual result came in at $459.1 million, up 10649.03% from the prior year.
- Non-Current Assets eased to $459.1 million in Q4 2025 per CRMD's latest filing, from $491.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $491.3 million in Q3 2025 and troughed at $1.2 million in Q2 2021.
- A 5-year average of $50.2 million and a median of $2.5 million in 2021 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets fell 1.9% in 2023, then soared 10986.07% in 2025.
- Over 5 years, Non-Current Assets stood at $2.5 million in 2021, then rose by 0.42% to $2.5 million in 2022, then grew by 4.92% to $2.6 million in 2023, then jumped by 63.67% to $4.3 million in 2024, then jumped by 10649.03% to $459.1 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $459.1 million, $491.3 million, and $4.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 423.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 423.50 Mn |
| Dec 31, 2025 | 459.09 Mn |
| Sep 30, 2025 | 491.33 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Dec 31, 2024 | 4.27 Mn |
| Sep 30, 2024 | 4.43 Mn |
| Jun 30, 2024 | 4.54 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Sep 30, 2023 | 2.37 Mn |
| Jun 30, 2023 | 2.41 Mn |
| Mar 31, 2023 | 2.45 Mn |
| Dec 31, 2022 | 2.49 Mn |
| Sep 30, 2022 | 2.41 Mn |
| Jun 30, 2022 | 2.39 Mn |
| Mar 31, 2022 | 2.43 Mn |
| Dec 31, 2021 | 2.48 Mn |
| Sep 30, 2021 | 2.40 Mn |
| Jun 30, 2021 | 1.17 Mn |